SDF-1和HER2在60例甲状腺乳头状癌中的表达及临床意义
Expression and Clinical Significance of SDF-1 and HER2 in 60 Cases of Papillary Thyroid Carcinoma
摘要: 目的：探讨SDF-1和HER2在甲状腺乳头状癌(PTC)中的表达及临床意义。方法：选取符合标准的60例甲状腺乳头状癌患者的癌组织及癌旁组织，采用免疫蛋白印迹法和免疫组化法分别检测SDF-1和HER2的表达水平，并分析其临床意义。结果：PTC组织中SDF-1与HER2的表达量均显著高于配对的癌旁组织(P < 0.05)。在伴有淋巴结转移、处于III~IV期或肿瘤直径较大的患者中，二者表达水平呈现明显上调趋势。SDF-1与HER2的表达强度均与肿瘤大小、淋巴结转移状态及临床分期呈显著正相关(P < 0.05)，而与患者的年龄和性别无统计学关联(P > 0.05)。结论：SDF-1和HER2在PTC的发生发展中有促癌作用，其表达水平与肿瘤大小、淋巴结转移、恶性程度密切相关。联合检测SDF-1和HER2有助于提高甲状腺癌的诊断率，可能成为PTC诊断及靶向治疗的潜在分子标志物。
Abstract: Objective: To investigate the expression and clinical significance of SDF‑1 and HER2 in papillary thyroid carcinoma (PTC). Methods: Cancer tissues and adjacent normal tissues from 60 patients with PTC meeting the inclusion criteria were collected. The expression levels of SDF‑1 and HER2 were detected by Western blotting and immunohistochemistry, respectively, and their clinical relevance was analyzed. Results: The expression levels of both SDF-1 and HER2 were significantly higher in PTC tissues than in matched adjacent normal tissues (P < 0.05). In patients with lymph node metastasis, advanced clinical stage (III~IV), or larger tumor diameter, the expression of both markers was significantly elevated. The expression levels of SDF-1 and HER2 showed a significant positive correlation with tumor size, lymph node metastasis status, and clinical stage (P < 0.05). In patients with lymph node metastasis, advanced clinical stage (III~IV), or larger tumor diameter, the expression of both markers was significantly elevated. The expression levels of SDF-1 and HER2 showed a significant positive correlation with tumor size, lymph node metastasis status, and clinical stage (P < 0.05), while no significant correlation was found with age or gender (P > 0.05). Conclusion: SDF‑1 and HER2 may play a promoting role in the development and progression of PTC, and their expression levels are closely related to tumor size, lymph node metastasis, and malignancy. Combined detection of SDF‑1 and HER2 could improve the diagnostic accuracy of thyroid cancer and may serve as potential molecular markers for the diagnosis and targeted therapy of PTC.
文章引用：赵玉娟, 邱杰. SDF-1和HER2在60例甲状腺乳头状癌中的表达及临床意义[J]. 临床医学进展, 2026, 16(4): 1091-1099. https://doi.org/10.12677/acm.2026.1641342

参考文献

[1] Miranda-Filho, A., Lortet-Tieulent, J., Bray, F., Cao, B., Franceschi, S., Vaccarella, S., et al. (2021) Thyroid Cancer Incidence Trends by Histology in 25 Countries: A Population-Based Study. The Lancet Diabetes & Endocrinology, 9, 225-234. [Google Scholar] [CrossRef] [PubMed]
[2] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[3] Siegel, R.L., Giaquinto, A.N. and Jemal, A. (2024) Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians, 74, 12-49. [Google Scholar] [CrossRef] [PubMed]
[4] Liao, T., Zeng, Y., Xu, W., Shi, X., Shen, C., Du, Y., et al. (2025) A Spatially Resolved Transcriptome Landscape during Thyroid Cancer Progression. Cell Reports Medicine, 6, Article ID: 102043. [Google Scholar] [CrossRef] [PubMed]
[5] Loberg, A.M., Xu, J.G., Chen, C.S., et al. (2025) An Integrated Single-Cell and Spatial Transcriptomic Atlas of Thyroid Cancer Progression Identifies Prognostic Fibroblast Subpopulations. bioRxiv. [Google Scholar] [CrossRef] [PubMed]
[6] 卢龙涛. 分子检测在甲状腺乳头状癌诊疗中的临床应用进展[J]. 山东第二医科大学学报, 2025, 47(5): 387-394.
[7] Bansal, R. and Saxena, U. (2022) Integrative Analysis of Potential Biomarkers Involved in the Progression of Papillary Thyroid Cancer. Applied Biochemistry and Biotechnology, 195, 2917-2932. [Google Scholar] [CrossRef] [PubMed]
[8] 田文, 阳泽龙. 甲状腺乳头状癌流行病学及诊疗焦点探讨[J]. 西安交通大学学报(医学版), 2024, 45(1): 44-48.
[9] Zahedi, A., Bondaz, L., Rajaraman, M., Leslie, W.D., Jefford, C., Young, J.E., et al. (2020) Risk for Thyroid Cancer Recurrence Is Higher in Men than in Women Independent of Disease Stage at Presentation. Thyroid, 30, 871-877. [Google Scholar] [CrossRef] [PubMed]
[10] 王流欢, 李思睿, 曾丽琴, 等. 甲状腺乳头状癌与负面情绪的关联性研究[J]. 中国普通外科杂志, 2024, 33(11): 1813-1824.
[11] 夏仲元. 甲状腺癌中医药诊治的现状与未来[J]. 北京中医药大学学报, 2022, 45(4): 353-359.
[12] 陈颖, 陈韵如, 陆钰原, 等. 基于德尔菲法构建《甲状腺癌中西医结合诊疗指南》临床问题[J]. 中国中西医结合杂志, 2025, 45(3): 268-276.
[13] 国家癌症中心, 国家肿瘤质控中心甲状腺癌质控专家委员会. 中国甲状腺癌规范诊疗质量控制指标(2022版) [J]. 中华肿瘤杂志, 2022, 44(9): 902-907.
[14] Castellone, M.D., Guarino, V., De Falco, V., Carlomagno, F., Basolo, F., Faviana, P., et al. (2004) Functional Expression of the CXCR4 Chemokine Receptor Is Induced by RET/PTC Oncogenes and Is a Common Event in Human Papillary Thyroid Carcinomas. Oncogene, 23, 5958-5967. [Google Scholar] [CrossRef] [PubMed]
[15] Lv, Y., Sui, F., Ma, J., Ren, X., Yang, Q., Zhang, Y., et al. (2016) Increased Expression of EHF Contributes to Thyroid Tumorigenesis through Transcriptionally Regulating HER2 and HER3. Oncotarget, 7, 57978-57990. [Google Scholar] [CrossRef] [PubMed]
[16] 钟娟芳, 徐娟, 曹亚. SDF-1/CXCR4在肿瘤信号转导中作用的分子机制[J]. 生命的化学, 2011, 31(3): 343-346.
[17] Zou, M., Qattan, A., Al-Alwan, M., Ghebeh, H., Binjumah, N., Al-Haj, L., et al. (2025) Genome-Wide Transcriptome Analysis and Drug Target Discovery Reveal Key Genes and Pathways in Thyroid Cancer Metastasis. Frontiers in Endocrinology, 16, Article 1514264. [Google Scholar] [CrossRef] [PubMed]
[18] Lee, R., Ellison, V., Forbes, D., Gao, C., Katanov, D., Kern, A., et al. (2024) Chemokine CXCL12 Activates CXC Receptor 4 Metastasis Signaling through the Upregulation of a CXCL12/CXCR4/MDMX (MDM4) Axis. Cancers, 16, Article 4194. [Google Scholar] [CrossRef] [PubMed]
[19] 杨建明, 黄静, 薛刚, 等. 甲状腺乳头状癌组织SDF-1和TFF3表达临床意义分析[J]. 中华肿瘤防治杂志, 2014, 21(12): 914-919.
[20] 薛刚, 黄静, 张慧芹, 等. 三叶因子3和SDF-1/CXCR4生物轴在甲状腺乳头状癌中的表达及临床意义[J]. 临床耳鼻咽喉头颈外科杂志, 2014, 28(2): 108-112.
[21] Kanda, S., Mochizuki, Y. and Kanetake, H. (2003) Stromal Cell-Derived Factor-1α Induces Tube-Like Structure Formation of Endothelial Cells through Phosphoinositide 3-Kinase. Journal of Biological Chemistry, 278, 257-262. [Google Scholar] [CrossRef] [PubMed]
[22] Hedge, S.S., Basu, A. and Chakraborty, S. (2014) The Role of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapies in Early-Stage Breast Cancer: Current Practices, Treatment De-Escalation, and Future Prospects. Cureus, 16, e55230.
[23] Aoki, Y., Nakayama, I. and Shitara, K. (2025) Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights. Current Oncology Reports, 27, 15-29. [Google Scholar] [CrossRef] [PubMed]
[24] Mlika, M., et al. (2015) The Interplay of EGFR, HER2, and VEGF in Thyroid Carcinoma: A Comprehensive Immunohistochemical Analysis. Pathology Research and Practice, 211, 956-962.
[25] Moasser, M.M. (2007) The Oncogene HER2: Its Signaling and Transforming Functions and Its Role in Human Cancer Pathogenesis. Oncogene, 26, 6469-6487. [Google Scholar] [CrossRef] [PubMed]
[26] Caria, P., Cantara, S., Frau, D., Pacini, F., Vanni, R. and Dettori, T. (2016) Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma. International Journal of Molecular Sciences, 17, Article 1759. [Google Scholar] [CrossRef] [PubMed]
[27] Dai, Y., Qiu, Y., Jiang, R., Xu, M., Zhao, L., Chen, G.G., et al. (2017) Concomitant High Expression of ERα36, EGFR and HER2 Is Associated with Aggressive Behaviors of Papillary Thyroid Carcinomas. Scientific Reports, 7, Article No. 12279. [Google Scholar] [CrossRef] [PubMed]

为你推荐